Insider buying last 90 days
No open-market insider purchases were filed for BMY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BMY insider filing, plotted on the chart in Gekko.Open BMY in Gekko
NYSE: BMY
Bristol-Myers Squibb (BMY) Stock Analysis & Forecast
Nov 4 close
$64.19+2.48 (+4.0%)
Gekko Brief
Nov 4 closeBristol-Myers Squibb closed at $64.19 on 4 November 2026, +4% on the day. The price sits above both the 50-day ($62.53) and 200-day ($60.06) moving averages, inside a 52-week range of $45.27 to $68.64. The GekkoIndex reads 51.3, in the Neutral zone, down 8.8 points over five sessions. Gekko Fair Value is $106.11, so the price is 39.5% below it.
The next earnings report is due on 4 February 2027, 91 days away (before open). Over the last 8 reports the company beat the earnings estimate 7 times, with an average move of 4.2% across the report. Seasonally, the next 20 trading days from this point averaged +2% over the last 5 years, rising in 3 of them.
20 firms rate the stock: 8 buy, 11 hold and 1 sell, with a consensus target of $65.25. A typical daily move is about 2.7%, and a typical 20-day move about 4.3%. On the swing-trade checklist, 4 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 4, 2026 close.
Bristol-Myers Squibb price vs fair value
Close $64.19200-day averageGekko Fair Value $106.11
Bristol-Myers Squibb quick facts
- Market cap
- $131.2B
- P/E ratio
- 14
- Forward P/E
- 9.5
- EPS, TTM
- $4.51
- Revenue, TTM
- $50.03B
- Profit margin
- 18.5%
- Dividend yield
- 4.03%
- Beta
- 0.19
- Volume
- 13.87M avg 12.11M
- 1-year return
- +39.5%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±4.3%
- 50-day average
- $62.53
- 200-day average
- $60.06
- Next earnings
- Feb 4 before open
- Shares outstanding
- 2.04B
Bristol-Myers Squibb swing-trade checklist
Bristol-Myers Squibb scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $64.19 is above the 50-day ($62.53) and 200-day ($60.06) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.3, Neutral
Reading 51.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
39.5% below
Price is 39.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 91 days
Next report Feb 4, 2027, 91 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.0% on average
From this point in the calendar, the next 20 trading days averaged +2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bristol-Myers Squibb stock chart and price history
Bristol-Myers Squibb closed at $64.19 on Nov 4, 2026, +39.5% over the past year, inside a 52-week range of $45.27 to $68.64.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +7.7%
- 3 months
- +0.1%
- 6 months
- +13.5%
- 1 year
- +39.5%
The full BMY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BMY in Gekko
Follow Bristol-Myers Squibb through every session
Put BMY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BMY in GekkoFree for 7 days. No credit card required.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a biopharmaceutical company engaged in researching, developing, and manufacturing medicines that it sells around the world. Its work covers areas such as blood disorders, cancer, heart and immune conditions, fibrosis, neurological disease, and infectious illness including COVID-19. Among its widely used products are Revlimid for multiple myeloma, Eliquis for stroke prevention and blood clot conditions, and Opdivo for a range of cancers, alongside therapies like Orencia for arthritis and Breyanzi, a cell-based immunotherapy for lymphoma.
Its broader lineup includes Pomalyst, Sprycel, Yervoy, Abraxane, Reblozyl, Empliciti, Zeposia, Inrebic, and Onureg, covering conditions from leukemia and melanoma to multiple sclerosis and anemia. These medicines reach patients through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government bodies, forming a broad commercial network rather than direct sales to individual consumers.
The company traces back to 1887 and was previously called Bristol-Myers Company. It is headquartered in New York, New York, and its shares are listed on the NYSE under the ticker BMY.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- bms.com
Bristol-Myers Squibb GekkoIndex: the smart money zone
Bristol-Myers Squibb’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.3, in the Neutral zone, down 8.8 points over five sessions.
51.3Neutral
Down 8.8 points over five sessions, from the Accumulation zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 39 | +0.2% | −1.9% | ||
| Accumulation | 225 | +0.3% | +1.6% | ||
| Neutral (current zone) | 400 | +0.3% | +0.8% | ||
| Distribution | 32 | −1.5% | −0.6% | ||
| Selling | 1 | Too few readings yet | |||
Average BMY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BMY price, zone by zone.Track BMY in Gekko
Is Bristol-Myers Squibb stock overvalued? Gekko Fair Value
Bristol-Myers Squibb trades 39.5% below Gekko Fair Value of $106.11, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Bristol-Myers Squibb shares are worth, recalculated every trading day.
$106.11
Gekko Fair Value, Nov 4, 2026
39.5% Undervalued
At the end of Aug 2026 the price was 3.2% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open BMY in Gekko
Bristol-Myers Squibb insider and Congress trading
No open-market insider purchases were filed for Bristol-Myers Squibb, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BMY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BMY, plotted on the chart in Gekko.Open BMY in Gekko
Buybacks
Bristol-Myers Squibb has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $98.00M
- As a share of market cap
- 0.07%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
2of the funds Gekko tracks hold BMY.
1added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Bristol-Myers Squibb earnings: next date and track record
Bristol-Myers Squibb reports on Feb 4, 2027, before the open (91 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Feb 4, 2027
Expected before the open, 91 days away
- EPS estimate
- $1.56
- Revenue estimate
- $12.66B
7 of 8reports beat the EPS estimate
±4.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- BMY reported Q3 2026 growth portfolio sales up 12%, driven by Reblozyl, Breyanzi, Opdualag, Qvantig, and Camzyos. Key milestones include FDA accelerated approval of Symvexis (first CELMoD) for multiple myeloma and Camzyos pediatric expansion. Four positive registrational study readouts in two months, including admilparant in IPF and Arlocell in relapsed/refractory multiple myeloma, signal pipeline momentum. Full year guidance was raised based on results strength.
- Guidance
- Management raised full year 2026 guidance based on strong Q3 results. Near-term catalysts include Mezigdomide PDUFA date of May 13, 2027, and Phase 3 progressive pulmonary fibrosis data expected Q1 next year.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $1.35 est $1.10 | $13.07B est $12.72B | +3.2% |
| Jul 30, 2026 | $2.04 est $1.59 | $12.97B est $11.74B | +3.5% |
| Apr 30, 2026 | $1.58 est $1.44 | $11.49B est $10.93B | +1.1% |
| Feb 5, 2026 | $1.26 est $1.63 | $12.50B est $12.28B | +7.6% |
| Oct 30, 2025 | $1.63 est $1.52 | $12.22B est $11.85B | +8.1% |
| Jul 31, 2025 | $1.46 est $1.09 | $12.27B est $11.44B | −3.8% |
| Apr 24, 2025 | $1.80 est $1.49 | $11.20B est $10.70B | −1.3% |
| Feb 6, 2025 | $1.67 est $1.47 | $12.34B est $11.57B | −4.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bristol-Myers Squibb stock forecast and analyst price targets
Analysts’ average 12-month price target for Bristol-Myers Squibb is $65.25, +1.7% from the last close, from 20 firms rating the stock in the last 90 days.
$65.25consensus 12-month target, +1.7% from the last close
Now $64.19Avg $65.25
Low $40High $80
Each firm’s latest rating in the last 90 days: 20 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | BMO Capital | $60 | −6.5% |
| Nov 2 | Bernstein | $61 | −5.0% |
| Oct 30 | BMO Capital | $60 | −6.5% |
| Oct 30 | Morgan Stanley | $40 | −37.7% |
| Oct 30 | Wells Fargo | $60 | −6.5% |
+0.8%average 20-day move after past Neutral readings
+2.0%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bristol-Myers Squibb seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Bristol-Myers Squibb averaged +2.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.4% | 2 of 5 |
| Next 10 trading days | 0.0% | 2 of 5 |
| Next 15 trading days | +0.5% | 3 of 5 |
| Next 20 trading days | +2.0% | 3 of 5 |
| Next 30 trading days | +3.1% | 3 of 5 |
For scale, BMY’s typical 20-trading-day move in either direction is about 4.3%.
Bristol-Myers Squibb market cap and key statistics
Bristol-Myers Squibb’s market cap is $131.2B, with a P/E ratio of 14 and revenue of $50.03B over the last twelve months.
Valuation
- Market cap
- $131.2B
- P/E ratio
- 14
- Forward P/E
- 9.5
- EPS, TTM
- $4.51
- Gekko Fair Value
- $106.11
Trading
- Volume
- 13.87M
- Avg volume, 20 days
- 12.11M
- 52-week high
- $68.64
- 52-week low
- $45.27
- Shares outstanding
- 2.04B
Financials
- Revenue, TTM
- $50.03B
- Profit margin
- 18.5%
- Return on equity
- 44%
- Quarterly earnings growth, YoY
- −2.8%
Risk and income
- Beta
- 0.19
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±4.3%
- Dividend yield
- 4.03%
Bristol-Myers Squibb stock news this week
Coverage of Bristol-Myers Squibb this week reads positive: 8 positive, 6 neutral and 1 negative headlines.
- Bristol Myers Squibb Co. stock outperforms competitors on strong trading dayMarketWatch, Nov 4
- Form 4 Bristol-Myers Squibb: Karin Shanahan (EVP, Chief Supply Chain & Ops) For: 1 NovemberInvesting.com Canada, Nov 4
- Bristol-Myers Squibb (NYSE:BMY) Breakout Setup Backed by Technical StrengthChartMill, Nov 4
- Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance Singapore, Nov 4
- Bristol Myers Squibb Company $BMY Stock Holdings Raised by Rakuten Investment Management Inc.MarketBeat, Nov 4
- Bristol Myers Squibb Shares Rose Even As Profit FellSimply Wall St, Nov 4
Bristol-Myers Squibb peers
Bristol-Myers Squibb’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
A peer links to its own page where one exists.
Bristol-Myers Squibb stock FAQ
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $131.2B at the Nov 4, 2026 close of $64.19, with 2.04B shares outstanding. The shares trade on a P/E ratio of 14.
What is the Bristol-Myers Squibb stock forecast?
The consensus analyst 12-month price target for Bristol-Myers Squibb is $65.25, +1.7% from the last close. Of the 20 firms that rated the stock in the last 90 days, 8 rate it a buy, 11 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Bristol-Myers Squibb stock overvalued or undervalued?
On Gekko’s estimate Bristol-Myers Squibb is undervalued: the Nov 4, 2026 close of $64.19 is 39.5% below Gekko Fair Value of $106.11. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bristol-Myers Squibb report earnings next?
Bristol-Myers Squibb is expected to report on Feb 4, 2027, before the market opens (91 days away). Analysts expect earnings of $1.56 per share on revenue of $12.66B. Bristol-Myers Squibb beat the earnings estimate in 7 of its last 8 reports, moving 4.2% on average across the report.
What is Bristol-Myers Squibb’s 52-week high and low?
Bristol-Myers Squibb’s 52-week high is $68.64 and its 52-week low is $45.27; it closed at $64.19 on Nov 4, 2026, +39.5% over the past year. Over the last five years the shares peaked at $81.44 on Dec 1, 2022.
Is Bristol-Myers Squibb stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bristol-Myers Squibb the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.